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**Keynote Address**Salle de bal ouest 17:00Keynote Address Speaker: Mark Wainberg, Ph.D., McGill University, Montreal, Quebec, Canada "The Next Decade of Antiviral Chemotherapy"  **Monday, April 14, 2008**  **Oral Session 1: Mini-Symposium: Novel Targets for HIV Therapy**Chairs: Tomas Cihlar, Ph.D. and Jose Este, Ph.D.Salle de bal ouest  08:00 a.m.--12:00 p.m. 08:001.APOBEC 3G: Innate Defense Against Retroviruses and RetroelementsWarner Greene, M.D.Gladstone Institute of Virology and Immunology, San Francisco, CA, USA   08:302.LEDGF/P75 as a Co-factor of HIV-1 Integrase and as a New Antiviral TargetZeger Debyser, M.D., Ph.D.IRC, KULAK and KULeuven, Leuven, Belgium   09:003.Trim 5 Alpha-mediated Late Restriction on HIV-1 ProductionYasuhiro Ikeda, Ph.D.Mayo College of Medicine, Rochester, MN, USA   09:30Break   10:004.Assembly of the Immature and Mature Viral Structure as Potential Antiviral TargetHans-Georg Krausslich, M.D.University of Heidelberg, Heidelberg, Germany   10:305.Late Stages of the HIV-1 Replication Cycle as Targets for Novel Antiviral AgentsEric Freed, Ph.D.HIV Drug Resistance Program, National Cancer Institute, Frederick, MD, USA   11:006.The Role of Vpu Protein in HIV-1 PathogenesisEdward Stephens, Ph.D.University of Kansas Medical Center, Kansas City, KS, USA   11:30Panel Discussion **Elion Award Lecture**Salle de bal ouest13:15Presentation of Award: Christopher McGuigan, Ph.D., President ISAR Awardee Lecture: Jan Balzarini, Ph.D., Rega Institute for Medical Research, Leuven, Belgium "The Potential of Carbohydrate Binding Agents as Novel Therapeutics to Treat Enveloped Virus Infections"  **Oral Session 2: Respiratory and Emerging Viruses**Chairs: Colleen Jonsson, Ph.D. and Simon Tucker, Ph.D.Salle de bal ouest  02:00--04:00 p.m. 14:007.Peptide-based Entry Inhibitors for InfluenzaThomas Voss^1^, Christopher LeBlanc^1^, Joseph Barbercheck^1^, Bryan Kaplan^1^, Russell Wilson^2^, Garry Robert^11^Tulane School of Medicine, New Orleans, LA, USA; ^2^Autoimmune Technologies, LLC, New Orleans, LA, USA   14:158.Factors Affecting Susceptibility of H5N1 Influenza Viruses to Neuraminidase Inhibitor OseltamivirElena Govorkova^1^, Natalia Ilyushina^1^, Jennifer McClaren^1^, Tri Naipospos^2^, Neziha Yilmas^3^, Bounlom Douangngeun^4^, Robert Webster^11^St. Jude Children\'s Research Hospital, Memphis, TN, USA; ^2^Indonesia National Committee on Avian Flu Control and Pandemic Influenza Preparedness, Jakarta, Indonesia; ^3^Virology and NIC of Turkey Refik Saydam Hygiene Institute, Ankara, Turkey; ^4^National Animal Health Centre, Vientiane, Laos   14:309.*In Vivo* Synergistic Combination Effect of Rimantadine and Oseltamivir Against Influenza A(H3N2) is Manifested in Several Dose RatiosLora Simeonova, Angel S. Galabov, Galina GegovaThe Stephan Angeloff Institute of Microbiology, Bulgarian Academy of Sciences, Sofia, Bulgaria   14:4510.Development of Novel Selective Parainfluenza Virus Hemagglutinin--Neuraminidase InhibitorsIrina V. Alymova^1^, Makiko Watanabe^1^, Vasiliy P. Mishin^1^, Y. Sudhakara Babu^2^, Allen Portner^11^Department of Infectious Diseases, St. Jude Children\'s Research Hospital, Memphis, TN, USA; ^2^BioCryst Pharmaceutical, Inc., Birmingham, AL, USA   15:0011.Evaluation of Interferon Inducers, Ribavirin and Mouse Hyperimmune Serum in a Pathogenesis/Lethal Mouse Model Using a Mouse-adapted SARS-CoVDale Barnard^1^, Craig Day^1^, Miles Wandersee^1^, Yohichi Kumaki^1^, Andres Salazar^21^Utah State University, Logan, UT, USA; ^2^Oncovir, Inc., Washington DC, DC, USA   15:1512.Therapies and Mechanisms of West Nile Virus Encephalitis and Neurological SequelaeJohn D. Morrey^1^, Venkatraman Sidharthan^1^, Hong Wang^1^, Neil Motter^1^, Jeffery O. Hall^1^, Robert D. Skinner^21^Institute Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, UT, USA; ^2^Center for Translational Neuroscience and Department of Neurobiology and Developmental Sciences, University of Arkansas Medical Sciences, Little Rock, AR, USA **Tuesday, April 15, 2008Oral Session 3: Hepatitis Viruses**Chairs: Phillip Furman, Ph.D. and Todd Parsley, Ph.D.Salle de bal ouest  08:00--11:30 a.m. 08:0013.Plenary: HCV Culture System and Antiviral DevelopmentTakaji WakitaDirector, National Institute of Infectious Diseases, Tokyo, Japan   08:3014.Identification of Halosalicylamide Derivatives as a Novel Class of Allosteric Inhibitors of HCV NS5B PolymeraseYaya Liu, Pamela Donner, Wen Jiang, Teresa Ng, Vijaya Gracias, Steve Baumeister, Paul Wiedeman, Linda Traphagen, Usha Warrior, Clarence Maring, Warren Kati, Stevan Djuric, Akhteruzzaman MollaAntiviral Research, Abbott Laboratories, Abbott Park, IL, USA   08:4515.Anti-Hepatitis C Virus Replicon Activity of Alkoxyalkyl Esters of (*S*)-HPMPA and Other Acyclic Nucleoside PhosphonatesDavid L. Wyles^1^, Robert T. Schooley^1^, Kelly A. Kaihara^1^, James R. Beadle^1,2^, Karl Y. Hostetler^1,21^Division of Infectious Disease, University of California, San Diego, La Jolla, CA, USA; ^2^Veterans Medical Research Foundation, San Diego, CA, USA   09:0016.Discovery of a Novel HCV Helicase Inhibitor by a De Novo Drug Design ApproachAndrea Brancale^1^, Dimitrios Vlachakis^1^, Sahar Kandil^1^, Sonia Biondaro^1^, Colin Berry^2^, Johan Neyts^31^The Welsh School of Pharmacy, Cardiff University, Cardiff, United Kingdom; ^2^School of Bioscience, Cardiff University, Cardiff, United Kingdom; ^3^Rega Institute for Medical Research, KULeuven, Leuven, Belgium   09:15Break   09:4517.PG 301029 Inhibits HCV Replication Through a Novel Late Stage Mechanism of ActionTodd B. Parsley, Lu Yang, Robert W. Buckheit Jr.ImQuest BioSciences, Inc., Frederick, MD, USA   10:0018.Different Incorporation Efficiencies for Nucleotide Analogs During HCV Polymerase RNA Synthesis Initiation and Elongation PhasesHan Ma^1^, Nicole Inocencio^1^, Vincent Leveque^1^, Genadiy Kalayanov^2^, David Smith^1^, Nick Cammack^1^, Nils Gunnar Johansson^2^, Klaus Klumpp^11^Roche, Palo Alto, CA, USA; ^2^Medivir AB, Huddinge, Sweden   10:1519.HCV RNA Helicase Requirement for NS3 Oligomerization is Substrate-dependent: Characterization of RNA Substrates with Different Double Strand Lengths and RNA Binding-dependent InhibitionJulie Hang, Yanli Yang, Vincent Leveque, Tony Giannetti, George Stepan, Nick Cammack, Klaus KlumppRoche, Palo Alto, CA, USA   10:3020.Evaluation of MK-7009, A Novel Macrocyclic Inhibitor of NS3/4A Protease, in the Chimpanzee Model of Chronic Hepatitis C Virus InfectionS. Ludmerer, D. Graham, L. Handt, C. Fandozzi, C. Burlein, N. Liverton, J. McCauley, J. Vacca, D. Hazuda, S. Carroll, D. OlsenMerck Research Labs, West Point, PA, USA   10:4521.Novel Five-membered Ring Imino Sugar Derivatives Inhibit Flaviviruses via Distinct MechanismsJinhong Chang^1^, Lijuan Wang^1^, Dongling Ma^1^, Robert Moriarty^3^, Benjamin Davis^4^, Peter Mason^5^, Baohua Gu^1^, Xiaodong Xu^6^, Ju-Tao Guo^1^, Timothy Block^1,21^Drexel University College of Medicine, Doylestown, PA, USA; ^2^Hepatitis B Foundation, Doylestown, PA, USA; ^3^University of Illinois, Chicago, IL, USA; ^4^University of Oxford, Oxford, United Kingdom; ^5^University of Texas Medical Branch, Galveston, TX, USA; ^6^Pharmabridge Inc., Doylestown, PA, USA   11:0022.A Novel and Selective Inhibitor of Hepatitis B Virus Surface Antigen SecretionAnne Marie Dougherty^1^, Haitao Guo^2^, Gael Westby^1^, Yuanjie Liu^2^, Ju-Tao Guo^2^, Anand S. Mehta^2^, Pamela Norton^2^, Baohua Gu^2^, Timothy M. Block^1,2^, Andrea Cuconati^11^Institute for Hepatitis and Virus Research, Doylestown, PA, USA; ^2^Drexel Institute for Biotechnology and Virology Research, Doylestown, PA, USA   11:1523.Preclinical Development of the Amphipathic DNA Polymer REP 9AC for the Treatment of Hepatitis B Virus InfectionFaseeha Noordeen^1^, Andrew Vaillant^2^, Jean-Marc Juteau^2^, Allison Jilbert^1,31^School of Molecular and Biomedical Science, The University of Adelaide, Adelaide, Australia; ^2^REPLICor Inc., Laval, QC, Canada; ^3^Infectious Diseases Laboratories, Institute of Medical and Veterinary Science, Adelaide, Australia **Clinical Symposium: Clinical Update on Antiviral Drugs**Chairs: Richard Pollard, Ph.D. and Ann Kwong, Ph.D.Salle de bal ouest  01:00--04:00 p.m. **Wednesday, April 16, 2008Prusoff Young Investigator Award Lecture**Salle de bal ouest 08:00Presentation of Award: Christopher McGuigan, Ph.D., President ISAR Awardee Lecture: Bruno Canard, Ph.D., Marseille, France "The Structure and Mechanism of RNA Virus Replication Enzymes: Endless Challenges for Drug Design" **Oral Session 4: Retroviruses**Chairs: Eric Freed, Ph.D. and Andrea Brancale, Ph.D.Salle de bal ouest  08:45--11:30 a.m. 08:4524.Characterization of a Novel Series of gp120 InhibitorsTanya Parkinson, Peter Stephenson, Chris Pickford, Thien Duc Tran, David Williams, David Fenwick, Juin Fok-Seang, Iain Gardner, Mike Westby, Don Middleton, Manos PerrosPfizer Global R&D, Sandwich, United Kingdom   09:0025.Novel Mechanism of Action of Pyrimidinediones Yields Enhanced Sensitivity to Multi-Drug Resistant Virus StrainsRobert W. Buckheit Jr., Lu Yang, Tracy L. Hartman, Karen M. WatsonImQuest BioSciences, Inc., Frederick, MD, USA   09:1526.Development of the Dual Acting Pyrimidinedione IQP0528 as a Vaginal Topical Anti-HIV MicrobicideKaren M. Watson, Lu Yang, Christa E. Buckheit, Robert W. Buckheit Jr.ImQuest BioSciences, Inc., Frederick, MD, USA   09:30Break   09:50Invitation to the 22nd ICAR, Miami Beach, FL, USA, John A. Secrist III, Ph.D.   10:00ISAR Business Meeting   10:1527.Enzyme-triggered CycloSal-PronucleotidesChris Meier^1^, Henning Jessen^1^, Nicolas Gisch^1^, Jan Balzarini^21^Institute of Organic Chemistry, University of Hamburg, Faculty of Science, Martin-Luther-King-Platz 6, 20146 Hamburg, Germany; ^2^Rega Institute for Medical Research, Catholic University of Leuven, Minderbroedersstraat 10, 3000 Leuven, Belgium   10:3028.Peptide-based Inhibitors of HIV-1 RT Dimerization and Pol-polyprotein MaturationPascal Clayette^1^, Audrey Agopian^2^, Nathalie Dereuddre-Bosquet^1^, Chritine Goffinet^3^, Rahima Yousfi^1^, Jérome Depollier^2^, Karen Storck^1^, Eric Gros^2^, Oliver Keppler^3^, Gilles Divita^21^Neurovirology Department, SPI-BIO, Fontenay aux Roses, France; ^2^CRBM, CNRS, Montpellier, France; ^3^Virology Department, University of Heidelberg, Heidelberg, Germany   10:4529.Low *In Vitro* Potential for Class-specific Toxicity of GS-9148, A Novel Nucleotide Reverse Transcriptase InhibitorGenevieve Laflamme^1^, Constantin Boojamra^1^, Lijun Zhang^1^, Hon Hui^1^, Robyn Fisher^2^, Richard Mackman^1^, Adrian Ray^1^, Tomas Cihlar^11^Gilead Sciences, Foster City, CA, USA; ^2^Vitron, Tucson, AZ, USA   11:0030.Pth15: An Interfacial Inhibitor of HIV-1 Integrase That Efficiently Blocks HIV-1 ReplicationEdwige Gros^1^, Edwire Guiot^1^, Audrey Agopian^1^, Eric Deprez^2^, Jean Francois Mouscadet^2^, Myriam Witvrouw^3^, Gilles Divita^11^UMR 5237 CNRS CRBM, Montpellier, France; ^2^LBPA-CNRS UMR 8113, Cachan, France; ^3^LMVD University of Leuven, Leuven, Belgium   11:1531.Effective Small Interfering RNAs Targeting Alpha V Integrin Inhibit HIV-1 ReplicationEduardo Pauls^1^, Ester Ballana^1^, Imma Clotet-Codina^1^, Berta Bosch^1^, Françoise Perron-Sierra^2^, Gordon Tucker^2^, Bonaventura Clotet^1^, Jose Esté^11^Retrovirology Laboratory IrsiCaixa, Badalona, Spain; ^2^Institut de Recherches Servier, Croissy sur Seine, France **Oral Session 5: Herpesvirsues and Poxviruses**Chairs: Rhonda Cardin, Ph.D. and Daniel Streblow, Ph.D.Salle de bal ouest  01:30--04:15 p.m. 13:3032.Plenary: Role of Angiogenesis and Wound Repair Factors in the Acceleration of Allograft Rejection by CytomegalovirusDaniel StreblowOregon Health and Science University, Beaverton, OR, USA   14:0033.Design, Synthesis and Evaluation of Novel Anti-VZV BCNAsChristopher McGuigan^1^, Marco Migliore^1^, Geoffrey Henson^2^, Joseph Patti^2^, Graciela Andrei^3^, Robert Snoeck^3^, Jan Balzarini^31^Cardiff University, Cardiff, United Kingdom; ^2^Inhibitex, Alpharetta, GA, USA; ^3^Rega Institute, Leuven, Belgium   14:1534.Maribavir Inhibits the Replication of Human Herpesvirus 6 and the Activity of the U69 Protein KinaseMark Prichard, Shannon Daily, Amie Perry, Earl KernUniversity of Alabama School of Medicine, Birmingham, AL, USA   14:3035.Antiviral Potency of ST-246 on the Production of Enveloped Orthopoxviruses and Characterization of ST-246 Resistant Vaccinia, Cowpox and Camelpox VirusesSophie Duraffour^1,2^, Solenne Vigne^2^, Aude Gracel^2^, Robert Jordan^3^, Dennis E. Hruby^3^, Jean-Marc Crance^2^, Daniel Garin^2^, Graciela Andrei^1^, Robert Snoeck^11^Rega Institute, Leuven, Belgium; ^2^CRSSA, Grenoble, France; ^3^SIGA Technologies, Inc., Corvallis, OR, USA   14:4536.Vaccinia DNA Polymerase is Profoundly Inhibited by Cidofovir and (*S*)-HPMPA Incorporated into the Template StrandWendy Magee^1^, Karl Hostetler^2^, David Evans^11^University of Alberta, Edmonton, AB, Canada; ^2^University of California, San Diego, CA, USA   15:0037.Development of a Model for the Study of Antivirals Against Molluscum Contagiosum Virus (MCV)Graciela Andrei^1^, Joos Van den Oord^2^, Rita De Vos^2^, Sophie Duraffour^1^, Arlette Blondeel^3^, Thiery Simonart^4^, Erik De Clercq^1^, Robert Snoeck^11^Rega Institute, Leuven, Belgium; ^2^Pathology Department, UZ Leuven, Leuven, Belgium; ^3^Dermatology Department, Saint Pierre Hospital, Brussels, Belgium; ^4^Dermatology Department, Erasmus Hospital, Brussels, Belgium   15:1538.*In Vitro* and *In Vivo* Efficacy of a Pyrimidine Nucleoside Analog Against Vaccinia and Cowpox VirusesDebra Quenelle^1^, Mark Prichard^1^, Kathy Keith^1^, Deborah Collins^1^, Terri Rice^1^, John Secrist^2^, Kamal Tiwari^2^, Joseph Maddry^2^, Earl Kern^11^The University of Alabama, School of Medicine, Birmingham, AL, USA; ^2^Southern Research Institute, Birmingham, AL, USA   15:3039.Effect of Treatment with the Cidofovir Analogue HDP-CDV in Guinea Pig Models of Cytomegalovirus InfectionFernando Bravo^1^, Rhonda Cardin^1^, Karl Hostetler^2^, David Bernstein^11^Cincinnati Children\'s Hospital Medical Center, University of Cincinnati, Division of Infectious Diseases, Cincinnati, OH, USA; ^2^Division of Infectious Diseases, University of California, San Diego, La Jolla, CA, USA   15:4540.A Single Accelerating Dose Study to Evaluate Safety and Pharmacokinetics (PK) of FV-100 in Healthy SubjectsS.M. Canas^1^, B. Wargin^2^, B. Boehlecke^3^, G. Henson^4^, J.M. Patti^4^, A.M. Morris^41^Prism Research, St. Paul, MN, USA; ^2^PK-PM Associates, Chapel Hill, NC, USA; ^3^Rho, Inc., Chapel Hill, NC, USA; ^4^Inhibitex, Inc., Alpharetta, GA, USA   16:0041.Single-Dose Safety and Pharmacokinetics of ST-246, A Novel Orthopoxvirus Egress InhibitorRobert Jordan^1^, Kevin Jones^1^, Tove' Bolken^1^, Deborah Tien^1^, Josef Strasser^2^, Shanthakumar T.R.^1^, Annie Frimm^3^, Michael Corrado^3^, Phoebe Strome^3^, Dennis Hruby^11^SIGA Technologies, Corvallis, OR, USA; ^2^TranTech Pharma, High Point, NC, USA; ^3^INC Research, Inc., Raleigh, NC, USA **Shotgun Poster Session**Chairs: Joseph Colacino, Ph.D. and Mark Prichard, Ph.D.Salle de bal ouest  04:15--06:15 p.m. **Thursday, April 17, 2008Oral Session 6: Other Viruses, Veterinary Viruses, and Late Breaker Presentations**Chairs: David Rock, DVM and Justin Julander, Ph.D.Salle de bal ouest  09:00--11:30 a.m. 08:0042.Plenary: Use of Antivirals for Control of High Consequence Animal DiseasesDaniel L. RockUniversity of Illinois at Urbana-Champaign, Urbana, IL, USA   08:3043.Design, Synthesis and Evaluation of 3-Ethynyl-Azole Nucleosides with Antiviral Activity Against HantavirusesJeffrey Arterburn^1^, Sidath Kumarapperuma^1^, Marjan Jeselnik^1^, Dong-Hoon Chung^2^, Yangie Sun^2^, Willaim Parker^2^, Yong Kyu Chu^2^, Colleen Jonsson^21^New Mexico State University, Las Cruces, NM, USA; ^2^Southern Research Institute, Birmingham, AL, USA   08:4544.A Derivate of the Antibiotic Doxorubicin Inhibits Dengue and Yellow Fever Virus Replication *In Vitro*Suzanne Kaptein^1^, Michael Jacobs^2^, Andrea Gamarnik^3^, Erik De Clercq^1^, Ferenc Sztaricskai^4^, Johan Neyts^11^Rega Institute, Leuven, Belgium; ^2^Royal Free and University College Medical School, London, United Kingdom; ^3^Fundacion Instituto Leloir, Buenos Aires, Argentina; ^4^University of Debrecen, Debrecen, Hungary   09:0045.One-third of the Surface of the Adenovirus Proteinase Contains Potential Drug Targets via a New Paradigm for Virion MaturationWalter MangelBrookhaven National Laboratory, Upton, NY, USA   09:15Break   09:4546.Efficacy of T-1106 or T-705, Alone or in Combination with Ribavirin, in the Treatment of Hamsters Infected with Yellow Fever VirusJustin Julander^1^, Kristiina Shafer^1^, Don Smee^1^, John Morrey^1^, Yousuke Furuta^21^Institute for Antiviral Research, Utah State University, Logan, UT, USA; ^2^Toyama Chemical Co. Ltd., Tokyo, Japan   10:00Late Breaker Presentation   10:15Late Breaker Presentation   10:30Late Breaker Presentation   10:45Late Breaker Presentation   11:00Late Breaker Presentation   11:15Late Breaker Presentation **Monday, April 14, 2008Poster Session I: Retroviruses, Hepatitis Viruses, Respiratory Viruses, Emerging Viruses, and Antiviral Methods**Salle de bal centre et est47.AlphaV Integrin-mediated Adhesion of Monocyte-derived Macrophages Influences HIV InfectionEster Ballana^1^, Eduardo Pauls^1^, Imma Clotet-Codina^1^, Berta Bosch^1^, Françoise Perron-Sierra^2^, Gordon Tucker^2^, Bonaventura Clotet^1^, Jose Esté^11^Retrovirology Laboratory IrsiCaixa, Badalona, Spain; ^2^Institut de Recherches Servier, Croissy sur Seine, France  48.Use of the HCV Cell Culture (HCVcc) System for Antiviral Drug TestingJodi Beattie, Jacob Simmons, Amine Noueiry, Paul OlivoApath LLC, St. Louis, MO, USA  49.*In Vitro* Vascular Leak as a Model of Viral Hemorrhagic FeverRebecca Brocato, Voss ThomasTulane School of Medicine, New Orleans, LA, USA  50.Resistance to Pyrimidinedione HIV Inhibitors Requires Multiple Mutations in Reverse Transcriptase, Envelope and Core ProteinsRobert W. Buckheit Jr., Christa E. Buckheit, Robert W. Buckheit III, Karen M. WatsonImQuest BioSciences, Inc., Frederick, MD, USA  51.Azaindole-based HIV-1 Integrase Specific Inhibitors Display Potent Anti-Retroviral ActivityScott Butler^1^, Michael Plewe^2^, Atsuo Kuki^2^, Teddy Johnson^2^, Qinghai Peng^2^, Dorothy Delisle^2^, Joanne Graham^2^, Hua Wu^2^, Amy Patick^21^Pfizer Global R&D, Sandwich Labs, Sandwich, United Kingdom; ^2^Pfizer Global R&D, La Jolla Labs, La Jolla, CA, USA  52.Establishment of a Cell-based HTS System for Discovery of Anti-Flavivirus DrugsYali Chen, Chris Harver, Travis Warren, Dennis Hruby, Robert JordanSIGA Technologies, Corvallis, OR, USA  53.Mevastatin Markedly Potentiates the Anti-HCV Activity of Selective Inhibitors of HCV Replication and Delays or Prevents the Emergence of Antiviral ResistanceLeen Delang, Johan NeytsRega Institute for Medical Research, KULeuven, B-3000 Leuven, Belgium  54.Comparative Virtual and Experimental Medium Throughput Screening for Hepatitis C Virus Polymerase InhibitorsHelene Dutartre^1^, Cecile Bussetta^1^, Stephane Betzi^2^, Joelle Boretto-Soler^1^, Claire Debarnot^1^, Mohamed Ben-Rahou^1^, Jean-Louis Romette^1^, Jean Claude Guillemot^1^, Karine Alvarez^1^, Xavier Morelli^2^, Bruno Canard^11^Department of Virology, AFMB-CNRS Universite d'Aix-Marseille, Marseille, France; ^2^CNRS-IBSM BIP laboratory, Marseille, France  55.MIV-170, A Novel NNRTI Exhibiting Tight Binding to HIV-1 Reverse Transcriptase (RT)Malin Elinder^1^, Helena Danielson^1^, Torsten Unge^2^, Guido VanHam^3^, Bo Öberg^41^Department of Biochemistry and Organic Chemistry, BMC, Uppsala University, Uppsala, Sweden; ^2^Department of Cell and Molecular Biology, BMC, Uppsala University, Uppsala, Sweden; ^3^Department of Microbiology, Institute of Tropical Medicine, Antwerpen, Belgium; ^4^Medivir AB, Huddinge, Sweden  56.Inverse Wavelet Transform in Virus--Cell Interaction ImagingAndriy Fedchuk^1^, Iryna Bartsykovska^1^, Alla Fedchuk^2^, Oleksandr Fedchuk^11^I.I. Mecnikov Odessa National University, Odessa, Ukraine; ^2^I.I. Mechnikov Ukrainian Anti-Plague Research Institute, Odessa, Ukraine  57.New Microscopic Description of Herpes Virus-Cell Dynamic SystemOleksandr Fedchuk^1^, Alla Fedchuk^2^, Iryna Bartsykovska^1^, Andriy Fedchuk^11^I.I. Mechnikov Odessa National University, Odessa, Ukraine; ^2^I.I. Mechnikov Ukrainian Research Anti-Plague Institute, Odessa, Ukraine 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